Gemcitabine Hydrochloride is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. Reference standards of Gemcitabine Hydrochloride API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => Gemcitabine Hydrochloride - Impurity B [catalogue_number] => PA 07 05020 [category_ids] => 76,75,70,78,82,83,85 [chemical_name] => [weight] => 263.20 [form] => C9H11F2N3O4 [cas] => 95058-85-8 [pslug] => 95058-85-8-gemcitabine-hydrochloride-impurity-b-pa0705020 [latest_product] => 0 [linkproducts] => 1 [offers_id] => 8 [offers_name] => Ready Stock [offers_status] => 1 [offers_start_date] => 2024-12-16 [offers_end_date] => 2024-12-31 [pageview] => 2 [offers_slug] => ready-stock [offers_product_id] => 36621 [offers_product_code] => PA 07 05020 [offers_master_id] => 8 [offer_percentage] => 20 % OFF [offers_product_main_cat] => Pharmaceutical Reference Standards )
Catalogue No.:PA 07 05020
CAS :
Molecular Formula : C9H11F2N3O4
Molecular Weight : 263.20
stdClass Object ( [pname] => Gemcitabine Hydrochloride - Impurity C [catalogue_number] => PA 07 05030 [category_ids] => 91,85,83,76,75,71 [chemical_name] => [weight] => 264.18 [form] => C9H10F2N2O5 [cas] => 114248-23-6 [pslug] => 114248-23-6-gemcitabine-hydrochloride-impurity-c-pa0705030 [latest_product] => 0 [linkproducts] => 0 [offers_id] => 8 [offers_name] => Ready Stock [offers_status] => 1 [offers_start_date] => 2024-12-16 [offers_end_date] => 2024-12-31 [pageview] => 2 [offers_slug] => ready-stock [offers_product_id] => 36622 [offers_product_code] => PA 07 05030 [offers_master_id] => 8 [offer_percentage] => 20 % OFF [offers_product_main_cat] => Pharmaceutical Reference Standards )
Catalogue No.:PA 07 05030
Molecular Formula : C9H10F2N2O5
Molecular Weight : 264.18
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
